Journal of gastrointestinal cancer · 2026
Predictors of Hepatic Decompensation Post-Y90 Treatment in Hepatocellular Carcinoma: New Insights into Segmental TARE and Post-Treatment Dosimetry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Afrasiabi Ali, Gholami Bahareh, Moon Andrew M, Villalobos Alex, Du Pisanie Johannes L, Harris Bryan, Yu Hyeon, Mauro David, Varela Paolo, Mohnasky Michael, Gad Sandra, Kokabi Nima, FRCPC
Аннотация
BACKGROUND: Transarterial radioembolization (TARE) with yttrium-90 (Y-90) microspheres is an established treatment for unresectable hepatocellular carcinoma (HCC). Although segmental TARE offers a favorable safety profile, hepatic decompensation remains a clinically important complication. This study aimed to identify clinical, laboratory, and post-treatment dosimetric predictors of hepatic decompensation following segmental Y-90 TARE.
METHODS: In this retrospective cohort study, 102 patients with HCC who underwent segmental Y-90 TARE between 2015 and 2025 were analyzed. Baseline demographic, clinical, laboratory, and imaging data were collected. Hepatic decompensation was defined as new-onset ascites, new or worsening hepatic encephalopathy, or total bilirubin > 3× the upper limit of normal within 2-4 months after TARE, in the absence of radiographic tumor progression. Post-treatment dosimetry was performed using SPECT/CT images. Univariate and multivariable logistic regression models were used to identify predictors of hepatic decompensation.
RESULTS: Hepatic decompensation occurred in 14 patients (13.7%). On univariate analysis, decompensation was associated with baseline hypoalbuminemia (< 3.5 g/dL), higher MELD and ALBI scores, Child-Pugh class B/C, INR ≥ 1.2, lower white blood cell count, and higher alkaline phosphatase levels. Because target doses and normal-parenchyma tolerances differ between microsphere types, post-treatment dosimetry and volumetry were analyzed separately by platform. In the glass microsphere cohort, patients who developed decompensation received a lower mean absorbed dose to the treated segment (236 Gy vs. 411 Gy, p = 0.03), whereas no significant dosimetric or volumetric differences were observed in the resin microsphere cohort. In multivariable analysis, baseline hypoalbuminemia (< 3.5 g/dL) was the only independent predictor of hepatic decompensation (OR = 7.98, 95% CI 1.16-80.39, p = 0.04).
CONCLUSION: In this retrospective cohort, hepatic decompensation following segmental Y-90 TARE appeared more strongly associated with impaired baseline hepatic reserve than with the post-treatment dosimetry parameters evaluated. Baseline hypoalbuminemia is a strong independent predictor of early hepatic decompensation and should be carefully considered during patient selection for radioembolization.
METHODS: In this retrospective cohort study, 102 patients with HCC who underwent segmental Y-90 TARE between 2015 and 2025 were analyzed. Baseline demographic, clinical, laboratory, and imaging data were collected. Hepatic decompensation was defined as new-onset ascites, new or worsening hepatic encephalopathy, or total bilirubin > 3× the upper limit of normal within 2-4 months after TARE, in the absence of radiographic tumor progression. Post-treatment dosimetry was performed using SPECT/CT images. Univariate and multivariable logistic regression models were used to identify predictors of hepatic decompensation.
RESULTS: Hepatic decompensation occurred in 14 patients (13.7%). On univariate analysis, decompensation was associated with baseline hypoalbuminemia (< 3.5 g/dL), higher MELD and ALBI scores, Child-Pugh class B/C, INR ≥ 1.2, lower white blood cell count, and higher alkaline phosphatase levels. Because target doses and normal-parenchyma tolerances differ between microsphere types, post-treatment dosimetry and volumetry were analyzed separately by platform. In the glass microsphere cohort, patients who developed decompensation received a lower mean absorbed dose to the treated segment (236 Gy vs. 411 Gy, p = 0.03), whereas no significant dosimetric or volumetric differences were observed in the resin microsphere cohort. In multivariable analysis, baseline hypoalbuminemia (< 3.5 g/dL) was the only independent predictor of hepatic decompensation (OR = 7.98, 95% CI 1.16-80.39, p = 0.04).
CONCLUSION: In this retrospective cohort, hepatic decompensation following segmental Y-90 TARE appeared more strongly associated with impaired baseline hepatic reserve than with the post-treatment dosimetry parameters evaluated. Baseline hypoalbuminemia is a strong independent predictor of early hepatic decompensation and should be carefully considered during patient selection for radioembolization.